Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupert Bartsch

Showing results (111-120 of 228) with videos related to

Pageof 23
Sort By:
BMC Cancer|March 28, 2006
Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatmentRupert Bartsch, Catharina Wenzel, Ursula Pluschnig, et al.
Breast Cancer Research and Treatment|September 22, 2009
Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG)Antoaneta Tomova, Rupert Bartsch, Thomas Brodowicz, et al.
Wiener Klinische Wochenschrift|July 1, 2005
Preoperative second-line chemotherapy induces objective responses in primary breast cancerCatharina Wenzel, Gottfried J Locker, Rupert Bartsch, et al.
The Breast Journal|January 29, 2013
Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancerAnna S Berghoff, Zsuzsanna Bago-Horvath, Peter Dubsky, et al.
Journal of Geriatric Oncology|October 18, 2024
Corticosteroid therapy in older adults with cancer: Expert recommendations from a task force of the International Society of Geriatric OncologyRupert Bartsch, Daniel Aletaha, Thorsten Fuereder, et al.
Breast Cancer Research and Treatment|October 25, 2006
Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSFCatharina Wenzel, Rupert Bartsch, Dagmar Hussian, et al.
Breast Care (Basel, Switzerland)|June 20, 2014
Alleviation of brain edema and restoration of functional independence by bevacizumab in brain-metastatic breast cancer: a case reportAnna S Berghoff, Cornelia Sax, Martin Klein, et al.
Breast Cancer Research and Treatment|October 10, 2006
Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancerRupert Bartsch, Catharina Wenzel, Gabriela Altorjai, et al.
Journal of Cancer Research and Clinical Oncology|May 29, 2004
Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot studyCatharina Wenzel, Dagmar Hussian, Rupert Bartsch, et al.
Anti-Cancer Drugs|March 5, 2005
Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancerCatharina Wenzel, Rupert Bartsch, Gottfried J Locker, et al.
Pageof 23

Showing results (111-120 of 228) with videos related to

Sort By:
Pageof 23
BMC Cancer|March 28, 2006
Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatmentRupert Bartsch, Catharina Wenzel, Ursula Pluschnig, et al.
Breast Cancer Research and Treatment|September 22, 2009
Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG)Antoaneta Tomova, Rupert Bartsch, Thomas Brodowicz, et al.
Wiener Klinische Wochenschrift|July 1, 2005
Preoperative second-line chemotherapy induces objective responses in primary breast cancerCatharina Wenzel, Gottfried J Locker, Rupert Bartsch, et al.
The Breast Journal|January 29, 2013
Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancerAnna S Berghoff, Zsuzsanna Bago-Horvath, Peter Dubsky, et al.
Journal of Geriatric Oncology|October 18, 2024
Corticosteroid therapy in older adults with cancer: Expert recommendations from a task force of the International Society of Geriatric OncologyRupert Bartsch, Daniel Aletaha, Thorsten Fuereder, et al.
Breast Cancer Research and Treatment|October 25, 2006
Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSFCatharina Wenzel, Rupert Bartsch, Dagmar Hussian, et al.
Breast Care (Basel, Switzerland)|June 20, 2014
Alleviation of brain edema and restoration of functional independence by bevacizumab in brain-metastatic breast cancer: a case reportAnna S Berghoff, Cornelia Sax, Martin Klein, et al.
Breast Cancer Research and Treatment|October 10, 2006
Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancerRupert Bartsch, Catharina Wenzel, Gabriela Altorjai, et al.
Journal of Cancer Research and Clinical Oncology|May 29, 2004
Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot studyCatharina Wenzel, Dagmar Hussian, Rupert Bartsch, et al.
Anti-Cancer Drugs|March 5, 2005
Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancerCatharina Wenzel, Rupert Bartsch, Gottfried J Locker, et al.
Pageof 23